{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:25:28Z","timestamp":1787120728427,"version":"build-2736575974"},"reference-count":46,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Higher dose naloxone products (HDN) have recently been approved and marketed in the United States; however, evidence on the relative advantage of these products to standard 4\u2009mg products has not been substantiated by prior research. People who use drugs are the primary beneficiaries and consumers of naloxone products. This study aimed to characterize their willingness to use HDN products and technical understanding of these products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and measurements<\/jats:title>\n                    <jats:p>We conducted in\u2010depth interviews with syringe service program clients following an interview guide. Interviews were recorded and transcribed before being analyzed using a hybrid deductive\u2010inductive qualitative approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Interviews were conducted in partnership with community\u2010based syringe service programs in three distinct regions of the state of Maryland, USA: a rural county, Baltimore city and a surrounding suburban community.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Twenty\u2010two interviews were completed. All participants had used opioids and responded to an overdose using naloxone in the past 3\u2009months. The majority of participants were men (73%), non\u2010Hispanic white (64%) and currently experiencing housing instability (59%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Participants demonstrated high willingness to use HDN, motivated by volatility in the local drug supply and perceived inefficiency of naloxone against potent synthetic opioids. Participants believed that the relative advantage of HDN was that it would reverse overdoses more quickly than existing products; however, many participants wanted increased control in overdose situations, including the ability to titrate and combine dosages to reduce the severity of precipitated withdrawal. Skepticism towards HDN products was rooted in general skepticism of pharmaceutical companies, as well as the belief that perceptions of lower dose naloxone being ineffective could be attributed to user error.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Development of novel overdose reversal products should be informed by the experiences of primary consumers and beneficiaries of these products. A high level of transparency is needed in the marketing of these products to promote consumer trust and confidence in their safety and utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.70447","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:25:19Z","timestamp":1777465519000},"page":"2494-2503","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u2018If you've ever experienced it, you'd feel differently\u2019: Exploring willingness and skepticism toward using higher dose naloxone products among people who use drugs in Maryland, United States"],"prefix":"10.1111","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6964-8150","authenticated-orcid":false,"given":"Laura N.","family":"Sisson","sequence":"first","affiliation":[{"name":"Department of Mental Health Johns Hopkins University Bloomberg School of Public Health  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Rousch","sequence":"additional","affiliation":[{"name":"Department of Health, Behavior and Society Johns Hopkins University Bloomberg School of Public Health  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-0159","authenticated-orcid":false,"given":"Lucas G.","family":"Hill","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Pittsburgh  Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire M.","family":"Zagorski","sequence":"additional","affiliation":[{"name":"College of Pharmacy The University of Texas at Austin  Austin TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Triece","sequence":"additional","affiliation":[{"name":"Department of Health, Behavior and Society Johns Hopkins University Bloomberg School of Public Health  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Rouhani","sequence":"additional","affiliation":[{"name":"College of Global Public Health New York University  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Owczarzak","sequence":"additional","affiliation":[{"name":"Department of Health, Behavior and Society Johns Hopkins University Bloomberg School of Public Health  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Health, Behavior and Society Johns Hopkins University Bloomberg School of Public Health  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin E.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Health, Behavior and Society Johns Hopkins University Bloomberg School of Public Health  Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","unstructured":"SpencerM Mini\u00f1oA WarnerM.Drug overdose deaths in the United States 2001\u20132021. Atlanta Georgia; 2022 Dec. Report.https:\/\/doi.org\/10.15620\/cdc:122556","DOI":"10.15620\/cdc:122556"},{"key":"e_1_2_10_3_1","unstructured":"AhmadFCisewskiJRossenLSuttonPNational Center for Health Statistics.Provisional Drug Overdose Death Counts.2024."},{"key":"e_1_2_10_4_1","unstructured":"National Center for Injury Prevention and Control. Centers for Disease Control and Prevention.2024Web\u2010based Injury Statistics Query and Reporting System (WISQARS) [online]."},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","unstructured":"SpencerM GarnettM Mini\u00f1oA.Drug overdose deaths in the United States 2002\u20132022. Atlanta GA;2023Dec. Report.https:\/\/doi.org\/10.15620\/cdc:135849","DOI":"10.15620\/cdc:135849"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.010"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000717"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.10.016"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.06.010"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-00980-5"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104154"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00879-7"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103457"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104587"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2022.2060433"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2018.1449053"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2021.1948558"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-019-00735-w"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7305a4"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14510"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2018.1555597"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2018.1449174"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/09687637.2022.2132134"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/PHH.0000000000000538"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00900-z"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40621-015-0041-8"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102968"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-025-01203-1"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2025.2491768"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00627-3"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103751"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000034"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104239"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2018.1439801"},{"key":"e_1_2_10_35_1","unstructured":"VERBI Software.Maxqda 2020. VERBI Software.2020."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/13645579.2016.1144401"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102951"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7217a2"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.759"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2014.10.024"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/00914509241254784"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.70060"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.23.0341"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103929"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2017.03.013"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/16066359.2019.1571193"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104253"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70447","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.70447","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:33:28Z","timestamp":1787117608000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.70447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/add.70447"],"URL":"https:\/\/doi.org\/10.1111\/add.70447","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}